Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABNCoV2 booster versus Comirnaty in previously vaccinated adults
2021-005504-36Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Jul 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abncov2 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Bavarian Nordic. Primary endpoint: Primary immunogenicity endpoint. Started Jul 2022; status: completed.
02
Drugs
abncov2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005504-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005504-36.